| Literature DB >> 27889448 |
Daniel A Ritt1, María T Abreu-Blanco2, Lakshman Bindu2, David E Durrant1, Ming Zhou2, Suzanne I Specht1, Andrew G Stephen2, Matthew Holderfield2, Deborah K Morrison3.
Abstract
Ras pathway signaling plays a critical role in cell growth control and is often upregulated in human cancer. The Raf kinases selectively interact with GTP-bound Ras and are important effectors of Ras signaling, functioning as the initiating kinases in the ERK cascade. Here, we identify a route for the phospho-inhibition of Ras/Raf/MEK/ERK pathway signaling that is mediated by the stress-activated JNK cascade. We find that key Ras pathway components, the RasGEF Sos1 and the Rafs, are phosphorylated on multiple S/TP sites in response to JNK activation and that the hyperphosphorylation of these sites renders the Rafs and Sos1 unresponsive to upstream signals. This phospho-regulatory circuit is engaged by cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative stress as well as by physiological regulators of the JNK cascade and may function as a signaling checkpoint to suppress the Ras pathway during conditions of cellular stress. Published by Elsevier Inc.Entities:
Keywords: ERK cascade; JNK cascade; Raf; Ras; Ras pathway; Sos; phosphorylation; rigosertib
Mesh:
Substances:
Year: 2016 PMID: 27889448 PMCID: PMC5135640 DOI: 10.1016/j.molcel.2016.10.029
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970